创新药概念逆势走强，港股创新药ETF（159567）早盘一度涨超3%

Core Viewpoint - The Hong Kong stock market opened slightly lower on October 31, but the pharmaceutical sector showed resilience, with the Hong Kong Innovative Drug ETF (159567) rising over 3% and trading volume exceeding 450 million yuan [1] Group 1: Market Performance - The Hong Kong Innovative Drug ETF (159567) experienced a significant increase, with a trading volume surpassing 450 million yuan by 9:55 AM [1] - Leading stocks in the sector included 3SBio, InnoCare Pharma, and Innovent Biologics, while a few stocks like Zai Lab and Kangji Medical showed slight declines [1] Group 2: Company Announcements - 3SBio announced a net profit increase of over 70% year-on-year for the first three quarters [1] Group 3: Policy and Industry Trends - The 2025 National Medical Insurance negotiations commenced on October 30, introducing a "commercial insurance innovative drug catalog" mechanism for the first time [1] - The Chinese innovative drug industry is increasingly integrating into the global pharmaceutical innovation system, transitioning from a focus on generic drugs to a significant role in global innovative drug business collaborations [1] - The industry has evolved from "following" and "running alongside" to "leading" in certain areas, supported by policy, clinical breakthroughs, and capital [1] Group 4: Investment Opportunities - The Hong Kong Innovative Drug ETF (159567) tracks the Guozheng Hong Kong Stock Connect Innovative Drug Index, reflecting the performance characteristics of listed companies in the innovative drug sector [1] - Investors can also access the Hong Kong Innovative Drug ETF linked funds (Class A: 023929, Class C: 023930) to capitalize on the upward opportunities in the sector [1]